



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Elarekibep

<b>Cat. No.:</b>	HY-P99935
<b>CAS No.:</b>	2485020-60-6
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Elarekibep (PRS-060) (AZD1402) is a high affinity, slowly dissociating, long-acting full antagonist of IL-4Ra. Elarekibep can be used for the research of T2 endotype asthma <sup>[1]</sup> .									
<b>In Vitro</b>	<p>Elarekibep (PRS-060) (0-10 <math>\mu</math>M) inhibits IL-4- or IL-13-induced STAT-6 phosphorylation with IC<sub>50</sub> values of 0.12 nM and 0.10 nM, respectively<sup>[1]</sup>.</p> <p>PRS-060 (0-10 <math>\mu</math>M) inhibits hIL-4 or hIL-13 induced proliferation of TF-1 cells with IC<sub>50</sub> values of 0.87 nM and 0.92 nM, respectively<sup>[1]</sup>.</p> <p>PRS-060 (0-10 <math>\mu</math>M) inhibits hIL-13 induced human epithelial cell mucus transdifferentiation with an IC<sub>50</sub> value of 0.3 nM<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
<b>In Vivo</b>	<p>PRS-060 (i.t; 2, 10, 50 <math>\mu</math>g) inhibits IL-13-induced eotaxin-1 expression in the lung and ovalbumin-induced acute allergic inflammation in the humanized mouse<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Triple-humanized mouse model<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>2, 10, 50 <math>\mu</math>g/mouse</td> </tr> <tr> <td>Administration:</td> <td>Intratracheal instillation (i.t)</td> </tr> <tr> <td>Result:</td> <td>Strongly suppressed acute allergic inflammation indices in triple humanized mice.</td> </tr> </table>		Animal Model:	Triple-humanized mouse model <sup>[1]</sup>	Dosage:	2, 10, 50 $\mu$ g/mouse	Administration:	Intratracheal instillation (i.t)	Result:	Strongly suppressed acute allergic inflammation indices in triple humanized mice.
Animal Model:	Triple-humanized mouse model <sup>[1]</sup>									
Dosage:	2, 10, 50 $\mu$ g/mouse									
Administration:	Intratracheal instillation (i.t)									
Result:	Strongly suppressed acute allergic inflammation indices in triple humanized mice.									

### REFERENCES

[1]. Gabriele Matschiner, et al. Elarekibep (PRS-060/AZD1402): a new class of inhaled Anticalin medicine targeting IL-4Ra for T2 endotype asthma. J Allergy Clin Immunol. 2022 Dec 30;S0091-6749(22)02588-X.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA